Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Nonpeptide agent · Amino acid or derivative
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
PubChem CID: 5961
Molecular formula: C5H10N2O3
IUPAC: (2S)-2,5-diamino-5-oxopentanoic acid
Source: PC-GLUTAMINE
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Amino acid/metabolic substrate for multiple cell types; metabolic need does not imply supplementation benefit in every illness.
Evidence and critical reading
Reported scientific and empirical uses
Gut and barrier · Immune modulation and inflammation · Replacement and nutritional context
Mentioned for gut, recovery and nutrition; distinguish enteral/parenteral nutrition from wellness blends.
Human evidence
REDOXS included 1,223 critically ill patients with multiorgan failure: early glutamine supplementation increased hospital/six-month mortality. Do not generalize “safe gut repair”.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
REDOXS included 1,223 critically ill patients with multiorgan failure: early glutamine supplementation increased hospital/six-month mortality. Do not generalize “safe gut repair”.
REDOXS included 1,223 critically ill patients with multiorgan failure: early glutamine supplementation increased hospital/six-month mortality. Do not generalize “safe gut repair”.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
Critical illness carries a material harm signal. Do not extrapolate a nutritional indication/oral exposure to every route/blend.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID23594003 · Randomized controlled trial
Critically ill patients with multiorgan failure.
IV/enteral, intensive-care context.
Higher hospital/six-month mortality with glutamine.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 1223
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Glutamine · 298 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07840521 · Investigating Near-Threshold Perception During Ultrasonic Deep Brain StimulationRegistry status: Not yet recruitingLast update posted: October 13, 2026Query verification: October 16, 2026
NCT07864571 · Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic CancerRegistry status: Not yet recruitingLast update posted: October 8, 2026Query verification: October 16, 2026
NCT07773246 · Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCDRegistry status: RecruitingLast update posted: October 8, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-GLUTAMINE
PubChem L-glutamine (CID 5961)
October 16, 2026
- PMID23594003
A randomized trial of glutamine and antioxidants in critically ill patients.
Heyland D, Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, Elke G, Berger MM, Day AG, Canadian Critical Care Trials Group.
October 16, 2026
- SEARCH-PUBMED-glutamine
October 16, 2026